Phase II Study of Daratumumab in Non-Hodgkin's Lymphoma Will Not Proceed to Stage 2 of Trial

Phase II Study of Daratumumab in Non-Hodgkin's Lymphoma Will Not Proceed to Stage 2 of Trial


Genmab A/S announced today that its collaboration partner for daratumumab, Janssen Biotech, Inc., has decided not to initiate stage 2 of the Phase II study of daratumumab in three types of relapsed or refractory non-Hodgkin's lymphoma . The study will not proceed to stage 2 as a data review showed that two cohorts of the study, investigating the use of daratumumab monotherapy in relapsed or refractory patients with follicular lymphoma , and with diffuse large B-cell lymphoma did not reach the predefined futility thresholds of overall response rates of 50%, and 30%, respectively.



from Biotech News